NKGEN BIOTECH INC. - COMMON STOCK

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

21 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site

19 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease

13 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease

12 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

NKGen Biotech Selected as Stalking Horse Bidder for NKMax

02 Dec 2024 15:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel

26 Nov 2024 15:15:00 By Nasdaq GlobeNewswire

NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

29 Oct 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)

15 Oct 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

08 Oct 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial

12 Sep 2024 07:05:59 By Nasdaq GlobeNewswire

NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report

22 Aug 2024 15:40:47 By Nasdaq GlobeNewswire

NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference

30 Jul 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference

18 Jul 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors

15 Jul 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024

12 Jun 2024 12:05:00 By Nasdaq GlobeNewswire

NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024

03 Jun 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 May 2024 16:05:00 By Nasdaq GlobeNewswire

NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease

20 May 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition

16 May 2024 07:05:00 By Nasdaq GlobeNewswire